ReviewCurrent medicinal chemistry2025
Current Evidence on Molecular Mechanisms of Andrographolide in Cancer.
Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Andrographolide suppresses chondrosarcoma cell migration and invasion by inhibiting the PI3K/Akt/mTOR signaling pathway and activating autophagy.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer, a diverse group of diseases characterized by abnormal cell growth and the potential to spread throughout the body, accounts for approximately 10 million deaths globally each year. Current cancer therapies, including chemotherapy, radiation, and various pharmacological treatments, present several challenges and potential side effects. It is important to differentiate these conventional methods, which often involve synthetic drugs, from adjuvant therapies that might be used in conjunction. As a result, there is an increasing interest in alternative therapies, particularly in agents derived from natural sources for cancer treatment. Secondary metabolites have shown promise in promoting the development of new clinical drugs with various anti-cancer mechanisms. This review focuses on the anti-cancer potential of the novel metabolite Andrographolide, extracted mainly from
Indexed as
Identifiers
38867528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.